Novartis joins forces with LA tech company Science 37 to launch virtual clinical trials
Novartis is pairing up with a Los Angeles tech company to launch 10 virtual clinical trials, in which patients will use cell phones to participate rather than traveling to hospitals and clinics.
The pharma giant is using tech made by Science 37, a software company that connects patients to researchers via mobile devices and telemedicine services.
Novartis was an early investor in Science 37 and is not new to the idea of virtual trials. Novartis owns 10% of Science 37 after joining its $29 million financing round with Sanofi, Amgen, Google, and others last April.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.